632 0.018 1.463 0.032 Race White (ref) mTOR inhibitor therapy Other 0.788 0.762 0.514 0.389 0.591 0.415 BMD https://www.selleckchem.com/products/azd5153.html T-score category ≤−2.5 4.900 <0.001 3.441 0.007 5.750 <0.001 >−2.5
(ref) Unknown 0.128 <0.001 0.180 <0.001 0.295 <0.001 Smoking Current smoker (ref) Former smoker 0.798 0.474 0.882 0.644 1.031 0.898 Never smoker 0.930 0.799 0.954 0.852 1.059 0.795 Unknown 0.225 0.011 0.286 0.007 0.383 0.010 Baseline BMI Under/normal weight (ref) Over weight 0.804 0.428 0.774 0.274 0.802 0.274 Obese 0.532 0.031 0.584 0.027 0.462 <0.001 Very obese 0.545 0.146 0.465 0.035 0.301 <0.001 Missing 0.845 0.521 0.671 0.067 0.535 <0.001 Charlson Comorbidity Index 1.034 0.269 1.040 0.122 1.033 0.138 Oral corticosteroid 1.669 0.014 1.358 0.092 1.270 0.136 Rheumatoid arthritis 1.650 0.254 2.179 0.031 1.765 0.092 BMI body mass index, BMD bone mineral density Results from logistic regressions for patients in the ICD-9-BMD are presented in Table 5. Treatment receipt was positively associated with age, with patients between the ages of 65 and 74 (OR = 1.18, p < 0.001) and 75 and older (OR = 1.57, p < 0.001) significantly Rabusertib manufacturer more likely to receive treatment compared with patients between 50 and 64. A low BMD T-score (≤−2.5) was significantly associated with an increased likelihood of receiving treatment (OR = 1.32, p = 0.002). Patients who used to smoke (OR = 0.76, p < 0.001) or who never smoked
(OR = 0.72, p < 0.001) were significantly less likely to receive
treatment than those who currently smoke. BMI was negatively associated with treatment. Overweight (OR = 0.81, p < 0.001), obese (OR = 0.54, p < 0.001), and very obese (OR = 0.46, p < 0.001) patients were less likely Orotidine 5′-phosphate decarboxylase to receive treatment than those who were underweight or normal weight. Patients with higher CCI (OR = 0.96, p < 0.001) were less likely to receive treatment, while those taking an oral corticosteroid (OR = 1.34, p < 0.001) and those with rheumatoid arthritis (OR = 1.40, p < 0.001) were more likely to receive treatment. Results were similar using treatment windows of 180 and 365 days. Table 5 Logistic regression for osteoporosis treatment—patients with low BMD or ICD-9 code Number of days from index date for treatment definition 90 days 180 days 365 days Odds ratio P value Odds ratio P value Odds ratio P value Age 50–64 (ref) 65–74 1.176 <0.001 1.197 <0.001 1.248 <0.001 75+ 1.565 <0.001 1.524 <0.001 1.514 <0.001 Race White (ref) Other 1.369 0.059 1.289 0.127 1.197 0.281 BMD T-score category ≤−2.5 1.322 0.002 1.533 <0.001 1.651 <0.001 >−2.5 (ref) Unknown 0.579 <0.001 0.591 <0.001 0.618 <0.001 Smoking Current smoker (ref) Former smoker 0.758 <0.001 0.754 <0.001 0.761 <0.001 Never smoker 0.715 <0.001 0.715 <0.001 0.711 <0.001 Unknown 0.336 <0.001 0.345 <0.001 0.356 <0.001 Baseline BMI Under/normal weight (ref) Over weight 0.805 <0.001 0.779 <0.001 0.739 <0.001 Obese 0.538 <0.001 0.513 <0.001 0.